Embedded Files
Drug uptake and distribution in some chemo-resistant tumors is low and various approaches have attempted to increase it, such as vascular normalization using anti-angiogenic therapy.
We have discovered an unusual class of organometallic agents, RAPTA compounds, with unique pharmacological properties and low general toxicities. At clinically relevant doses RAPTA normalizes tumor blood vessels without significantly inducing anti-angiogenic activity and vessel pruning, thereby offering a similar benefit as antiangiogenic compounds, but without the translational difficulties.
The key protein targets of RAPTA have now been identified. RAPTA compounds were not designed to inhibit these targets, so we expect that much better inhibitors can be obtained. So, we intend to develop microfluidic-based bioassays for these targets, providing rapid and reliable results and sustainable improved cost-effective easy-to-use methodologies. We will screen putative libraries of compounds and from the key hits will design and synthesize efficient inhibitors RAPTA compounds that will be characterized. Then they will be validated in relevant in vitro and in vivo models. This project will be performed at LAQV, REQUIMTE, UP and at EPFL.
Page updated
Google Sites
Report abuse